Specialty Pharmacy

Pharmacy benefit manager study indicates that moving patients with hemophilia from standard half-life to extended half-life coagulation factor products carries a significant cost increase.

Nivolumab showed major tumor responses in early stage lung cancer patients and an increase in anti-tumor T-cells that remained after the tumor was removed.

Top news of the day from across the health care landscape.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Ray Bailey, BPharm, RPh, Pharmacists Director at Florida Cancer Specialists, discusses important considerations for managing oral chemotherapy care plans and improving adherence in patients.

With the growing use of digital patient identification to conduct business it comes as no surprise that many people have sought to take advantage of Medicare members.

New treatments for cystic fibrosis, migraines, and multiple sclerosis expected to help push specialty drug costs on the pharmacy benefit to nearly 50% of total drug spending by 2020.

Epidiolex would be the first plant-based cannabinoid approved by the FDA and would create a new category of anti-epileptic drugs.

Christopher W. Kennedy, MSM, Chief Operating Officer, Heritage Biologics, speaks about the positive effects telehealth can have on specialty pharmacy patients.

Top news of the day from across the health care landscape.

Novel technique leverages limited DNA sequences from HIV to spark a priming effect within the patient’s immune response.

The 2019 Benefit and Payment Parameters final rule allows states to select their own Essential Health Benefits benchmark plans.

Top news of the day from across the health care landscape.

The FDA has granted priority review to the application for the treatment of patients with small cell lung cancer whose disease has progressed after 2 or more prior lines of therapy.

New analysis from a phase 3 trial reports that oral, once-daily siponimod (BAF312) consistently reduced disability progression in patients with secondary progressive multiple sclerosis.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Pembrolizumab (Keytruda) met its primary endpoint in the pivotal phase 3 KEYNOTE-042 trial.

Top news of the day from across the health care landscape.

Osimertinib surpassed standard of care with a median progression-free survival of 18.9 months in clinical trials.

HDL cholesterol is known as the good kind, but too much or too little could negatively impact the immune system.

Officials with the FDA have approved fostamatinib disodium hexahydrate (Tavalisse, Rigel) for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment

Emicizumab-kxwh (Hemlibra, Genentech) is the first medication to show superior efficacy compared with prior factor VIII prophylaxis in intra-patient comparisons.

Most of the survey respondents were unaware of oncology drug shortages but would want to be told about any therapy substitutions caused by short supply.

Top news of the day from across the health care landscape.

Until now, there has been little guidance on the safe prescribing of opioids in the inpatient, non-operative setting.

Some studies have suggested that patients with HIV have not only a higher risk of lung cancer, but also an increased risk of mortality from lung cancer than patients without HIV.

In its phase 3 trial, Pfizer’s axitinib (Inlyta) did not achieve disease-free survival in patients at high risk of recurrent renal cell carcinoma after nephrectomy.

The findings could lead to broader access to cancer drug Z-endoxifen for further clinical study

Top news of the day from across the health care landscape.

Opdivo and Yervoy combination is the first and only treatment to show significantly superior survival compared with sunitinib in intermediate- and poor-risk advanced RCC.